{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T11:54:35Z","timestamp":1791806075452,"version":"4.3.4"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Type-1 and type-3 interferons (IFNs) are important for control of viral replication; however, less is known about the role of Type-2 IFN (IFN\u03b3) in anti-viral immunity. We previously observed that lung infection with <jats:italic>Mycobacterium bovis<\/jats:italic> BCG achieved though intravenous (<jats:italic>iv<\/jats:italic>) administration provides strong protection against SARS-CoV-2 in mice yet drives low levels of type-1 IFNs but robust IFN\u03b3. Here we examine the role of ongoing IFN\u03b3 responses to pre-established bacterial infection on SARS-CoV-2 disease outcomes in two murine models. We report that IFN\u03b3 is required for <jats:italic>iv<\/jats:italic> BCG induced reduction in pulmonary viral loads, an outcome dependent on IFN\u03b3 receptor expression by non-hematopoietic cells. Importantly, we show that BCG infection prompts pulmonary epithelial cells to upregulate IFN-stimulated genes with reported anti-viral activity in an IFN\u03b3-dependent manner, suggesting a possible mechanism for the observed protection. Finally, we confirm the anti-viral properties of IFN\u03b3 by demonstrating that the recombinant cytokine itself provides strong protection against SARS-CoV-2 challenge when administered intranasally. Together, our data show that a pre-established IFN\u03b3 response within the lung is protective against SARS-CoV-2 infection, suggesting that concurrent or recent infections that drive IFN\u03b3 may limit the pathogenesis of SARS-CoV-2 and supporting possible prophylactic uses of IFN\u03b3 in COVID-19 management.<\/jats:p>","DOI":"10.1038\/s41467-023-43447-0","type":"journal-article","created":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T13:04:23Z","timestamp":1702386263000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Bacterial-induced or passively administered interferon gamma conditions the lung for early control of SARS-CoV-2"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1238-1552","authenticated-orcid":false,"given":"Kerry L.","family":"Hilligan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9993-1347","authenticated-orcid":false,"given":"Sivaranjani","family":"Namasivayam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5354-9270","authenticated-orcid":false,"given":"Chad S.","family":"Clancy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1245-4459","authenticated-orcid":false,"given":"Samuel I.","family":"Old","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0793-1049","authenticated-orcid":false,"given":"Victoria","family":"Peluf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5465-8113","authenticated-orcid":false,"given":"Eduardo P.","family":"Amaral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6544-5268","authenticated-orcid":false,"given":"Sandra D.","family":"Oland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"O\u2019Mard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9817-3852","authenticated-orcid":false,"given":"Julie","family":"Laux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4839-9386","authenticated-orcid":false,"given":"Melanie","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole L.","family":"Garza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2140-6205","authenticated-orcid":false,"given":"Bernard A. P.","family":"Lafont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reed F.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4301-4640","authenticated-orcid":false,"given":"Carl G.","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7360-1809","authenticated-orcid":false,"given":"Dragana","family":"Jankovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7571-9253","authenticated-orcid":false,"given":"Olivier","family":"Lamiable","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0311-3233","authenticated-orcid":false,"given":"Katrin D.","family":"Mayer-Barber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7053-2895","authenticated-orcid":false,"given":"Alan","family":"Sher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,12]]},"reference":[{"key":"43447_CR1","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270\u2013273 (2020).","journal-title":"Nature"},{"key":"43447_CR2","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271\u2013280 e278 (2020).","journal-title":"Cell"},{"key":"43447_CR3","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/s41591-020-01227-z","volume":"27","author":"C Muus","year":"2021","unstructured":"Muus, C. et al. Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and demographics. Nat. Med. 27, 546\u2013559 (2021).","journal-title":"Nat. Med."},{"key":"43447_CR4","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.cell.2020.04.035","volume":"181","author":"CGK Ziegler","year":"2020","unstructured":"Ziegler, C. G. K. et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell 181, 1016\u20131035 e1019 (2020).","journal-title":"Cell"},{"key":"43447_CR5","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.cell.2020.05.042","volume":"182","author":"YJ Hou","year":"2020","unstructured":"Hou, Y. J. et al. SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract. Cell 182, 429\u2013446 e414 (2020).","journal-title":"Cell"},{"key":"43447_CR6","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1146\/annurev-virology-092818-015756","volume":"6","author":"JW Schoggins","year":"2019","unstructured":"Schoggins, J. W. Interferon-stimulated genes: what do they all do? Annu. Rev. Virol. 6, 567\u2013584 (2019).","journal-title":"Annu. Rev. Virol."},{"key":"43447_CR7","doi-asserted-by":"publisher","first-page":"e1003773","DOI":"10.1371\/journal.ppat.1003773","volume":"9","author":"S Crotta","year":"2013","unstructured":"Crotta, S. et al. Type I and type III interferons drive redundant amplification loops to induce a transcriptional signature in influenza-infected airway epithelia. PLoS Pathog. 9, e1003773 (2013).","journal-title":"PLoS Pathog."},{"key":"43447_CR8","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3389\/fimmu.2017.00259","volume":"8","author":"S Makris","year":"2017","unstructured":"Makris, S., Paulsen, M., Johansson, C. & Type, I. Interferons as regulators of lung inflammation. Front. Immunol. 8, 259 (2017).","journal-title":"Front. Immunol."},{"key":"43447_CR9","doi-asserted-by":"crossref","unstructured":"Israelow, B. et al. Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling. J. Exp. Med. 217, e20201241 (2020).","DOI":"10.1084\/jem.20201241"},{"key":"43447_CR10","doi-asserted-by":"publisher","first-page":"110799","DOI":"10.1016\/j.celrep.2022.110799","volume":"39","author":"Z Chong","year":"2022","unstructured":"Chong, Z. et al. Nasally delivered interferon-lambda protects mice against infection by SARS-CoV-2 variants including Omicron. Cell Rep. 39, 110799 (2022).","journal-title":"Cell Rep."},{"key":"43447_CR11","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1126\/science.abc6027","volume":"369","author":"J Hadjadj","year":"2020","unstructured":"Hadjadj, J. et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science 369, 718\u2013724 (2020).","journal-title":"Science"},{"key":"43447_CR12","unstructured":"Zhang, Q. et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 370, eabd4570 (2020)."},{"key":"43447_CR13","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1093\/cid\/ciaa453","volume":"71","author":"TR O\u2019Brien","year":"2020","unstructured":"O\u2019Brien, T. R. et al. Weak induction of interferon expression by severe acute respiratory syndrome coronavirus 2 supports clinical trials of interferon-lambda to treat early coronavirus disease 2019. Clin. Infect. Dis. 71, 1410\u20131412 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"43447_CR14","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1002\/eji.202249913","volume":"52","author":"PP Ogger","year":"2022","unstructured":"Ogger, P. P. et al. Type I interferon receptor signalling deficiency results in dysregulated innate immune responses to SARS-CoV-2 in mice. Eur. J. Immunol. 52, 1768\u20131775 (2022).","journal-title":"Eur. J. Immunol."},{"key":"43447_CR15","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/ni1001-907","volume":"2","author":"C Bogdan","year":"2001","unstructured":"Bogdan, C. Nitric oxide and the immune response. Nat. Immunol. 2, 907\u2013916 (2001).","journal-title":"Nat. Immunol."},{"key":"43447_CR16","doi-asserted-by":"publisher","first-page":"D1040","DOI":"10.1093\/nar\/gks1215","volume":"41","author":"I Rusinova","year":"2013","unstructured":"Rusinova, I. et al. Interferome v2.0: an updated database of annotated interferon-regulated genes. Nucleic Acids Res. 41, D1040\u2013D1046 (2013).","journal-title":"Nucleic Acids Res."},{"key":"43447_CR17","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1084\/jem.178.5.1725","volume":"178","author":"MB Graham","year":"1993","unstructured":"Graham, M. B. et al. Response to influenza infection in mice with a targeted disruption in the interferon gamma gene. J. Exp. Med. 178, 1725\u20131732 (1993).","journal-title":"J. Exp. Med."},{"key":"43447_CR18","doi-asserted-by":"publisher","first-page":"6637","DOI":"10.1128\/JVI.72.8.6637-6645.1998","volume":"72","author":"A Bot","year":"1998","unstructured":"Bot, A., Bot, S. & Bona, C. A. Protective role of gamma interferon during the recall response to influenza virus. J. Virol. 72, 6637\u20136645 (1998).","journal-title":"J. Virol."},{"key":"43447_CR19","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.virol.2014.07.039","volume":"468-470","author":"SF Glineur","year":"2014","unstructured":"Glineur, S. F. et al. Sustained inflammation and differential expression of interferons type I and III in PVM-infected interferon-gamma (IFNgamma) gene-deleted mice. Virology 468-470, 140\u2013149 (2014).","journal-title":"Virology"},{"key":"43447_CR20","doi-asserted-by":"publisher","first-page":"e1000849","DOI":"10.1371\/journal.ppat.1000849","volume":"6","author":"MB Frieman","year":"2010","unstructured":"Frieman, M. B. et al. SARS-CoV pathogenesis is regulated by a STAT1 dependent but a type I, II and III interferon receptor independent mechanism. PLoS Pathog. 6, e1000849 (2010).","journal-title":"PLoS Pathog."},{"key":"43447_CR21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/mi.2017.41","volume":"11","author":"D Califano","year":"2018","unstructured":"Califano, D. et al. IFN-gamma increases susceptibility to influenza A infection through suppression of group II innate lymphoid cells. Mucosal Immunol. 11, 209\u2013219 (2018).","journal-title":"Mucosal Immunol."},{"key":"43447_CR22","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1161\/01.CIR.97.10.1017","volume":"97","author":"N Yamamoto","year":"1998","unstructured":"Yamamoto, N., Shibamori, M., Ogura, M., Seko, Y. & Kikuchi, M. Effects of intranasal administration of recombinant murine interferon-gamma on murine acute myocarditis caused by encephalomyocarditis virus. Circulation 97, 1017\u20131023 (1998).","journal-title":"Circulation"},{"key":"43447_CR23","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0928-8244(03)00358-4","volume":"40","author":"G Liu","year":"2004","unstructured":"Liu, G. et al. Prevention of lethal respiratory vaccinia infections in mice with interferon-alpha and interferon-gamma. FEMS Immunol. Med. Microbiol. 40, 201\u2013206 (2004).","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"43447_CR24","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12931-015-0282-7","volume":"16","author":"KM Eichinger","year":"2015","unstructured":"Eichinger, K. M. et al. Alveolar macrophages support interferon gamma-mediated viral clearance in RSV-infected neonatal mice. Respir. Res. 16, 122 (2015).","journal-title":"Respir. Res."},{"key":"43447_CR25","doi-asserted-by":"crossref","unstructured":"Beer, J. et al. Impaired immune response drives age-dependent severity of COVID-19. J. Exp. Med. 219, e20220621 (2022).","DOI":"10.1084\/jem.20220621"},{"key":"43447_CR26","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1089\/jir.2009.0084","volume":"30","author":"ID Weiss","year":"2010","unstructured":"Weiss, I. D. et al. IFN-gamma treatment at early stages of influenza virus infection protects mice from death in a NK cell-dependent manner. J. Interferon Cytokine Res. 30, 439\u2013449 (2010).","journal-title":"J. Interferon Cytokine Res."},{"key":"43447_CR27","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.medj.2021.09.003","volume":"2","author":"A van Laarhoven","year":"2021","unstructured":"van Laarhoven, A. et al. Interferon gamma immunotherapy in five critically ill COVID-19 patients with impaired cellular immunity: a case series. Med 2, 1163\u20131170 e1162 (2021).","journal-title":"Med"},{"key":"43447_CR28","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s00134-021-06377-3","volume":"47","author":"LS Nguyen","year":"2021","unstructured":"Nguyen, L. S., Ait Hamou, Z., Gastli, N., Chapuis, N. & Pene, F. Potential role for interferon gamma in the treatment of recurrent ventilator-acquired pneumonia in patients with COVID-19: a hypothesis. Intensive Care Med. 47, 619\u2013621 (2021).","journal-title":"Intensive Care Med."},{"key":"43447_CR29","doi-asserted-by":"crossref","unstructured":"Myasnikov, A. L., Berns, S. A., Talyzin, P. A. & Ershov, F. I. [Interferon gamma in the treatment of patients with moderate COVID-19]. Vopr. Virusol. 66, 47\u201354 (2021).","DOI":"10.36233\/0507-4088-24"},{"key":"43447_CR30","doi-asserted-by":"publisher","first-page":"e1009427","DOI":"10.1371\/journal.ppat.1009427","volume":"17","author":"P Bessiere","year":"2021","unstructured":"Bessiere, P. et al. Intranasal type I interferon treatment is beneficial only when administered before clinical signs onset in the SARS-CoV-2 hamster model. PLoS Pathog. 17, e1009427 (2021).","journal-title":"PLoS Pathog."},{"key":"43447_CR31","doi-asserted-by":"crossref","unstructured":"Mao, T. et al. A stem-loop RNA RIG-I agonist protects against acute and chronic SARS-CoV-2 infection in mice. J. Exp. Med. 219, e20211818 (2022).","DOI":"10.1084\/jem.20211818"},{"key":"43447_CR32","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa2209760","volume":"388","author":"G Reis","year":"2023","unstructured":"Reis, G. et al. Early treatment with pegylated interferon lambda for Covid-19. N. Engl. J. Med. 388, 518\u2013528 (2023).","journal-title":"N. Engl. J. Med."},{"key":"43447_CR33","doi-asserted-by":"crossref","unstructured":"Hilligan, K. L. et al. Intravenous administration of BCG protects mice against lethal SARS-CoV-2 challenge. J. Exp. Med. 219, e20211862 (2022).","DOI":"10.1084\/jem.20211862"},{"key":"43447_CR34","doi-asserted-by":"publisher","first-page":"107733","DOI":"10.1016\/j.isci.2023.107733","volume":"26","author":"AK Singh","year":"2023","unstructured":"Singh, A. K. et al. Intravenous BCG vaccination reduces SARS-CoV-2 severity and promotes extensive reprogramming of lung immune cells. iScience 26, 107733 (2023).","journal-title":"iScience"},{"key":"43447_CR35","doi-asserted-by":"crossref","unstructured":"Zhang, B. Z. et al. Bacillus Calmette-Guerin-induced trained immunity protects against SARS-CoV-2 challenge in K18-hACE2 mice. JCI Insight. 7, e157393 (2022).","DOI":"10.1172\/jci.insight.157393"},{"key":"43447_CR36","doi-asserted-by":"crossref","unstructured":"Lee, A. et al. Integrated organ immunity: antigen-specific CD4-T cell-derived IFN-\u03b3 induced by BCG imprints prolonged lung innate resistance against respiratory viruses. bioRxiv, https:\/\/www.biorxiv.org\/content\/10.1101\/2023.07.31.551354v1 (2023).","DOI":"10.1101\/2023.07.31.551354"},{"key":"43447_CR37","doi-asserted-by":"publisher","first-page":"e1010093","DOI":"10.1371\/journal.ppat.1010093","volume":"18","author":"O Rosas Mejia","year":"2022","unstructured":"Rosas Mejia, O. et al. Mice infected with Mycobacterium tuberculosis are resistant to acute disease caused by secondary infection with SARS-CoV-2. PLoS Pathog. 18, e1010093 (2022).","journal-title":"PLoS Pathog."},{"key":"43447_CR38","doi-asserted-by":"publisher","first-page":"e0307522","DOI":"10.1128\/spectrum.03075-22","volume":"10","author":"RE Hildebrand","year":"2022","unstructured":"Hildebrand, R. E. et al. Superinfection with SARS-CoV-2 has deleterious effects on mycobacterium bovis BCG immunity and promotes dissemination of mycobacterium tuberculosis. Microbiol. Spectr. 10, e0307522 (2022).","journal-title":"Microbiol. Spectr."},{"key":"43447_CR39","doi-asserted-by":"crossref","unstructured":"Baker, P. J. et al. Co-infection of mice with SARS-CoV-2 and Mycobacterium tuberculosis limits early viral replication but does not affect mycobacterial loads. Front. Immunol. 14, 1240419 (2023).","DOI":"10.3389\/fimmu.2023.1240419"},{"key":"43447_CR40","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1016\/j.cell.2021.02.042","volume":"184","author":"Q Li","year":"2021","unstructured":"Li, Q. et al. SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape. Cell 184, 2362\u20132371.e9 (2021).","journal-title":"Cell"},{"key":"43447_CR41","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/s41392-021-00848-1","volume":"6","author":"T Pan","year":"2021","unstructured":"Pan, T. et al. Infection of wild-type mice by SARS-CoV-2 B.1.351 variant indicates a possible novel cross-species transmission route. Signal Transduct. Target. Ther. 6, 420 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"43447_CR42","doi-asserted-by":"crossref","unstructured":"Stone, S. et al. SARS-CoV-2 variants of concern infect the respiratory tract and induce inflammatory response in wild-type laboratory mice. Viruses 14, 27 (2021).","DOI":"10.3390\/v14010027"},{"key":"43447_CR43","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1016\/j.immuni.2021.06.003","volume":"54","author":"R Wang","year":"2021","unstructured":"Wang, R. et al. Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species. Immunity 54, 1611\u20131621 e1615 (2021).","journal-title":"Immunity"},{"key":"43447_CR44","doi-asserted-by":"publisher","first-page":"869809","DOI":"10.3389\/fimmu.2022.869809","volume":"13","author":"C Zhang","year":"2022","unstructured":"Zhang, C. et al. The SARS-CoV-2 B.1.351 variant can transmit in rats but not in mice. Front. Immunol. 13, 869809 (2022).","journal-title":"Front. Immunol."},{"key":"43447_CR45","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1002\/eji.1830250331","volume":"25","author":"CH Ladel","year":"1995","unstructured":"Ladel, C. H. et al. Contribution of alpha\/beta and gamma\/delta T lymphocytes to immunity against Mycobacterium bovis bacillus Calmette Guerin: studies with T cell receptor-deficient mutant mice. Eur. J. Immunol. 25, 838\u2013846 (1995).","journal-title":"Eur. J. Immunol."},{"key":"43447_CR46","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1084\/jem.178.4.1435","volume":"178","author":"R Kamijo","year":"1993","unstructured":"Kamijo, R. et al. Mice that lack the interferon-gamma receptor have profoundly altered responses to infection with Bacillus Calmette-Guerin and subsequent challenge with lipopolysaccharide. J. Exp. Med. 178, 1435\u20131440 (1993).","journal-title":"J. Exp. Med."},{"key":"43447_CR47","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1038\/s41590-020-0778-2","volume":"21","author":"ES Winkler","year":"2020","unstructured":"Winkler, E. S. et al. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat. Immunol. 21, 1327\u20131335 (2020).","journal-title":"Nat. Immunol."},{"key":"43447_CR48","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1016\/j.molcel.2021.04.008","volume":"81","author":"L Martin-Sancho","year":"2021","unstructured":"Martin-Sancho, L. et al. Functional landscape of SARS-CoV-2 cellular restriction. Mol. Cell 81, 2656\u20132668.e8 (2021).","journal-title":"Mol. Cell"},{"key":"43447_CR49","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1038\/s41564-020-0769-y","volume":"5","author":"S Pfaender","year":"2020","unstructured":"Pfaender, S. et al. LY6E impairs coronavirus fusion and confers immune control of viral disease. Nat. Microbiol. 5, 1330\u20131339 (2020).","journal-title":"Nat. Microbiol."},{"key":"43447_CR50","doi-asserted-by":"crossref","unstructured":"Mar, K. B. et al. LY6E is a pan-coronavirus restriction factor in the respiratory tract. Nat. Microbiol. 8, 1587\u20131599 (2023).","DOI":"10.1038\/s41564-023-01431-w"},{"key":"43447_CR51","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1371\/journal.pmed.0050026","volume":"5","author":"M Rottman","year":"2008","unstructured":"Rottman, M. et al. IFN-gamma mediates the rejection of haematopoietic stem cells in IFN-gammaR1-deficient hosts. PLoS Med. 5, e26 (2008).","journal-title":"PLoS Med."},{"key":"43447_CR52","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41586-022-04802-1","volume":"606","author":"E Sefik","year":"2022","unstructured":"Sefik, E. et al. Inflammasome activation in infected macrophages drives COVID-19 pathology. Nature 606, 585\u2013593 (2022).","journal-title":"Nature"},{"key":"43447_CR53","unstructured":"Salina, A. C. G. et al. Efferocytosis of SARS-CoV-2-infected dying cells impairs macrophage anti-inflammatory functions and clearance of apoptotic cells. Elife 11, e74443 (2022)."},{"key":"43447_CR54","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir, M. E., Butte, M. J., Freeman, G. J. & Sharpe, A. H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677\u2013704 (2008).","journal-title":"Annu. Rev. Immunol."},{"key":"43447_CR55","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1634\/stemcells.2006-0644","volume":"25","author":"C Holmes","year":"2007","unstructured":"Holmes, C. & Stanford, W. L. Concise review: stem cell antigen-1: expression, function, and enigma. Stem Cells 25, 1339\u20131347 (2007).","journal-title":"Stem Cells"},{"key":"43447_CR56","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/nature06553","volume":"451","author":"SJ Neil","year":"2008","unstructured":"Neil, S. J., Zang, T. & Bieniasz, P. D. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451, 425\u2013430 (2008).","journal-title":"Nature"},{"key":"43447_CR57","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/iid3.92","volume":"4","author":"WD Mahauad-Fernandez","year":"2016","unstructured":"Mahauad-Fernandez, W. D. & Okeoma, C. M. The role of BST-2\/Tetherin in host protection and disease manifestation. Immun. Inflamm. Dis. 4, 4\u201323 (2016).","journal-title":"Immun. Inflamm. Dis."},{"key":"43447_CR58","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","volume":"19","author":"A Garcia-Diaz","year":"2017","unstructured":"Garcia-Diaz, A. et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep. 19, 1189\u20131201 (2017).","journal-title":"Cell Rep."},{"key":"43447_CR59","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41590-020-00840-x","volume":"22","author":"IE Galani","year":"2021","unstructured":"Galani, I. E. et al. Untuned antiviral immunity in COVID-19 revealed by temporal type I\/III interferon patterns and flu comparison. Nat. Immunol. 22, 32\u201340 (2021).","journal-title":"Nat. Immunol."},{"key":"43447_CR60","doi-asserted-by":"crossref","unstructured":"Lokugamage, K. G. et al. Type I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV. J. Virol. 94, e01410-20 (2020).","DOI":"10.1128\/JVI.01410-20"},{"key":"43447_CR61","doi-asserted-by":"publisher","first-page":"e2221652120","DOI":"10.1073\/pnas.2221652120","volume":"120","author":"M Moriyama","year":"2023","unstructured":"Moriyama, M., Lucas, C., Monteiro, V. S., Yale, S.-C.-G. S. I. & Iwasaki, A. Enhanced inhibition of MHC-I expression by SARS-CoV-2 Omicron subvariants. Proc. Natl Acad. Sci. USA 120, e2221652120 (2023).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"43447_CR62","doi-asserted-by":"publisher","first-page":"109126","DOI":"10.1016\/j.celrep.2021.109126","volume":"35","author":"M Hayn","year":"2021","unstructured":"Hayn, M. et al. Systematic functional analysis of SARS-CoV-2 proteins uncovers viral innate immune antagonists and remaining vulnerabilities. Cell Rep. 35, 109126 (2021).","journal-title":"Cell Rep."},{"key":"43447_CR63","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.cell.2020.06.010","volume":"182","author":"J Sun","year":"2020","unstructured":"Sun, J. et al. Generation of a broadly useful model for COVID-19 pathogenesis, vaccination, and treatment. Cell 182, 734\u2013743 e735 (2020).","journal-title":"Cell"},{"key":"43447_CR64","doi-asserted-by":"crossref","unstructured":"Nelson, C. E. et al. IL-10 suppresses T cell expansion while promoting tissue-resident memory cell formation during SARS-CoV-2 infection in rhesus macaques. bioRxiv https:\/\/www.biorxiv.org\/content\/10.1101\/2022.09.13.507852v1 (2022).","DOI":"10.1101\/2022.09.13.507852"},{"key":"43447_CR65","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/S0022-3476(99)70064-8","volume":"135","author":"SE Dorman","year":"1999","unstructured":"Dorman, S. E. et al. Viral infections in interferon-gamma receptor deficiency. J. Pediatr. 135, 640\u2013643 (1999).","journal-title":"J. Pediatr."},{"key":"43447_CR66","unstructured":"Bastard, P. et al. A loss-of-function IFNAR1 allele in Polynesia underlies severe viral diseases in homozygotes. J. Exp. Med. 219, e20220028 (2022)."},{"key":"43447_CR67","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1056\/NEJM199612263352604","volume":"335","author":"E Jouanguy","year":"1996","unstructured":"Jouanguy, E. et al. Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guerin infection. N. Engl. J. Med. 335, 1956\u20131961 (1996).","journal-title":"N. Engl. J. Med."},{"key":"43447_CR68","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1056\/NEJM199612263352602","volume":"335","author":"MJ Newport","year":"1996","unstructured":"Newport, M. J. et al. A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N. Engl. J. Med. 335, 1941\u20131949 (1996).","journal-title":"N. Engl. J. Med."},{"key":"43447_CR69","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.cell.2020.09.050","volume":"183","author":"SR Leist","year":"2020","unstructured":"Leist, S. R. et al. A mouse-adapted SARS-CoV-2 induces acute lung injury and mortality in standard laboratory mice. Cell 183, 1070\u20131085 e1012 (2020).","journal-title":"Cell"},{"key":"43447_CR70","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41586-020-2708-8","volume":"586","author":"KH Dinnon 3rd","year":"2020","unstructured":"Dinnon, K. H. 3rd et al. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature 586, 560\u2013566 (2020).","journal-title":"Nature"},{"key":"43447_CR71","doi-asserted-by":"publisher","first-page":"110502","DOI":"10.1016\/j.celrep.2022.110502","volume":"38","author":"E Kaufmann","year":"2022","unstructured":"Kaufmann, E. et al. BCG vaccination provides protection against IAV but not SARS-CoV-2. Cell Rep. 38, 110502 (2022).","journal-title":"Cell Rep."},{"key":"43447_CR72","doi-asserted-by":"publisher","first-page":"108530","DOI":"10.1016\/j.celrep.2020.108530","volume":"33","author":"MA Florez","year":"2020","unstructured":"Florez, M. A. et al. Interferon gamma mediates hematopoietic stem cell activation and niche relocalization through BST2. Cell Rep. 33, 108530 (2020).","journal-title":"Cell Rep."},{"key":"43447_CR73","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.1016\/j.celrep.2019.11.021","volume":"29","author":"SA Stifter","year":"2019","unstructured":"Stifter, S. A. et al. Visualizing the selectivity and dynamics of interferon signaling in vivo. Cell Rep. 29, 3539\u20133550 e3534 (2019).","journal-title":"Cell Rep."},{"key":"43447_CR74","doi-asserted-by":"publisher","first-page":"e1387","DOI":"10.1002\/cti2.1387","volume":"11","author":"NL Messina","year":"2022","unstructured":"Messina, N. L. et al. Off-target effects of bacillus Calmette-Guerin vaccination on immune responses to SARS-CoV-2: implications for protection against severe COVID-19. Clin. Transl. Immunol. 11, e1387 (2022).","journal-title":"Clin. Transl. Immunol."},{"key":"43447_CR75","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1165\/ajrcmb.17.1.f132","volume":"17","author":"TS Blackwell","year":"1997","unstructured":"Blackwell, T. S. & Christman, J. W. The role of nuclear factor-kappa B in cytokine gene regulation. Am. J. Respir. Cell Mol. Biol. 17, 3\u20139 (1997).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"43447_CR76","doi-asserted-by":"publisher","first-page":"1232764","DOI":"10.3389\/fimmu.2023.1232764","volume":"14","author":"KL Hilligan","year":"2023","unstructured":"Hilligan, K. L., Namasivayam, S. & Sher, A. BCG mediated protection of the lung against experimental SARS-CoV-2 infection. Front. Immunol. 14, 1232764 (2023).","journal-title":"Front. Immunol."},{"key":"43447_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00406-4","volume":"6","author":"C Counoupas","year":"2021","unstructured":"Counoupas, C. et al. A single dose, BCG-adjuvanted COVID-19 vaccine provides sterilising immunity against SARS-CoV-2 infection. NPJ Vaccines 6, 143 (2021).","journal-title":"NPJ Vaccines"},{"key":"43447_CR78","doi-asserted-by":"publisher","first-page":"e938","DOI":"10.1093\/cid\/ciac182","volume":"75","author":"S Moorlag","year":"2022","unstructured":"Moorlag, S. et al. Efficacy of BCG vaccination against respiratory tract infections in older adults during the coronavirus disease 2019 pandemic. Clin. Infect. Dis. 75, e938\u2013e946 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"43447_CR79","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1093\/cid\/ciac881","volume":"76","author":"AM Blossey","year":"2023","unstructured":"Blossey, A. M. et al. VPM1002 as prophylaxis against severe respiratory tract infections including coronavirus disease 2019 in the elderly: a phase 3 randomized, double-blind, placebo-controlled, multicenter clinical study. Clin. Infect. Dis. 76, 1304\u20131310 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"43447_CR80","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.cmi.2022.04.009","volume":"28","author":"T Ten Doesschate","year":"2022","unstructured":"Ten Doesschate, T. et al. Bacillus Calmette-Guerin vaccine to reduce healthcare worker absenteeism in COVID-19 pandemic, a randomized controlled trial. Clin. Microbiol. Infect. 28, 1278\u20131285 (2022).","journal-title":"Clin. Microbiol. Infect."},{"key":"43447_CR81","doi-asserted-by":"publisher","first-page":"e0035623","DOI":"10.1128\/mbio.00356-23","volume":"14","author":"J Claus","year":"2023","unstructured":"Claus, J. et al. BCG vaccination of health care workers does not reduce SARS-CoV-2 infections nor infection severity or duration: a randomized placebo-controlled trial. mBio 14, e0035623 (2023).","journal-title":"mBio"},{"key":"43447_CR82","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1056\/NEJMoa2212616","volume":"388","author":"LF Pittet","year":"2023","unstructured":"Pittet, L. F. et al. Randomized trial of BCG vaccine to protect against Covid-19 in health care workers. N. Engl. J. Med. 388, 1582\u20131596 (2023).","journal-title":"N. Engl. J. Med."},{"key":"43447_CR83","unstructured":"Koekenbier, E. L. et al. Bacillus Calmette-Guerin vaccine for prevention of COVID-19 and other respiratory tract infections in older adults with comorbidities: a randomized controlled trial. Clin. Microbiol. Infect. 29, 781\u2013788 (2023)."},{"key":"43447_CR84","doi-asserted-by":"publisher","first-page":"841868","DOI":"10.3389\/fimmu.2022.841868","volume":"13","author":"LRB Dos Anjos","year":"2022","unstructured":"Dos Anjos, L. R. B. et al. Efficacy and safety of BCG revaccination With M. bovis BCG Moscow to prevent COVID-19 infection in health care workers: a randomized phase II clinical trial. Front. Immunol. 13, 841868 (2022).","journal-title":"Front. Immunol."},{"key":"43447_CR85","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ijid.2023.02.014","volume":"130","author":"AP Santos","year":"2023","unstructured":"Santos, A. P. et al. The effect of BCG vaccination on infection and antibody levels against SARS-CoV-2-the results of ProBCG: a multicenter randomized clinical trial in Brazil. Int. J. Infect. Dis. 130, 8\u201316 (2023).","journal-title":"Int. J. Infect. Dis."},{"key":"43447_CR86","doi-asserted-by":"publisher","first-page":"6911","DOI":"10.1016\/j.vaccine.2014.10.041","volume":"32","author":"DA Kaveh","year":"2014","unstructured":"Kaveh, D. A., Garcia-Pelayo, M. C. & Hogarth, P. J. Persistent BCG bacilli perpetuate CD4 T effector memory and optimal protection against tuberculosis. Vaccine 32, 6911\u20136918 (2014).","journal-title":"Vaccine"},{"key":"43447_CR87","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1093\/infdis\/jis012","volume":"205","author":"AM Minassian","year":"2012","unstructured":"Minassian, A. M. et al. A human challenge model for mycobacterium tuberculosis using mycobacterium bovis bacille Calmette-Guerin. J. Infect. Dis. 205, 1035\u20131042 (2012).","journal-title":"J. Infect. Dis."},{"key":"43447_CR88","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1093\/infdis\/jiaa030","volume":"221","author":"B Freyne","year":"2020","unstructured":"Freyne, B. et al. Neonatal BCG vaccination reduces interferon-gamma responsiveness to heterologous pathogens in infants from a randomized controlled trial. J. Infect. Dis. 221, 1999\u20132009 (2020).","journal-title":"J. Infect. Dis."},{"key":"43447_CR89","doi-asserted-by":"crossref","unstructured":"Barman, T. K. et al. Lethal synergy between SARS-CoV-2 and Streptococcus pneumoniae in hACE2 mice and protective efficacy of vaccination. JCI Insight. 7, e159422 (2022).","DOI":"10.1172\/jci.insight.159422"},{"key":"43447_CR90","doi-asserted-by":"publisher","first-page":"657006","DOI":"10.3389\/fmed.2021.657006","volume":"8","author":"WM Song","year":"2021","unstructured":"Song, W. M. et al. COVID-19 and tuberculosis coinfection: an overview of case reports\/case series and meta-analysis. Front. Med. (Lausanne) 8, 657006 (2021).","journal-title":"Front. Med. (Lausanne)"},{"key":"43447_CR91","doi-asserted-by":"publisher","first-page":"e2005","DOI":"10.1093\/cid\/ciaa1198","volume":"73","author":"Western Cape Department of Health in collaboration with the National Institute for Communicable Diseases, S.A.","year":"2021","unstructured":"Western Cape Department of Health in collaboration with the National Institute for Communicable Diseases, S.A. Risk factors for coronavirus disease 2019 (COVID-19) death in a population Cohort Study from the Western Cape Province, South Africa. Clin. Infect. Dis. 73, e2005\u2013e2015 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"43447_CR92","doi-asserted-by":"crossref","unstructured":"Busnadiego, I. et al. Antiviral activity of type I, II, and III interferons counterbalances ACE2 inducibility and restricts SARS-CoV-2. mBio 11, e01928-20 (2020).","DOI":"10.1128\/mBio.01928-20"},{"key":"43447_CR93","doi-asserted-by":"crossref","unstructured":"Xu, D. et al. PLSCR1 is a cell-autonomous defence factor against SARS-CoV-2 infection. Nature 619, 819\u2013827 (2023).","DOI":"10.1038\/s41586-023-06322-y"},{"key":"43447_CR94","doi-asserted-by":"crossref","unstructured":"Corman, V. M. et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 25, 2000045 (2020).","DOI":"10.2807\/1560-7917.ES.2020.25.3.2000045"},{"key":"43447_CR95","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/oxfordjournals.aje.a118408","volume":"27","author":"LJ Reed","year":"1938","unstructured":"Reed, L. J. & Muench, H. A simple method of estimating fifty per cent endpoints12. Am. J. Epidemiol. 27, 493\u2013497 (1938).","journal-title":"Am. J. Epidemiol."},{"key":"43447_CR96","unstructured":"Becton, D.a.C. FlowJo\u2122 Software for Mac. version 10 ed: Becton, Dickinson and Company (2023)."},{"key":"43447_CR97","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573\u20133587 e3529 (2021).","journal-title":"Cell"},{"key":"43447_CR98","unstructured":"Wickham, H., Fran\u00e7ois, R., Henry, L., M\u00fcller, K. & Vaughan, D. dplyr: a grammar of data manipulation (2023)."},{"key":"43447_CR99","doi-asserted-by":"crossref","unstructured":"Wickham, H. ggplot2: Elegant Graphics for Data Analysis. Springer\u2013Verlag, New York (2016).","DOI":"10.1007\/978-3-319-24277-4"},{"key":"43447_CR100","unstructured":"Kassambara, A. ggpubr: \u2018ggplot2\u2019 Based Publication Ready Plots. https:\/\/cran.r-project.org\/web\/packages\/ggpubr\/index.html (2023)."},{"key":"43447_CR101","unstructured":"Slowikowski, K. ggrepel: automatically position non-overlapping text labels with ggplot2. https:\/\/cran.r-project.org\/web\/packages\/ggrepel\/ggrepel.pdf (2023)."},{"key":"43447_CR102","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/s42003-020-01625-6","volume":"4","author":"N Borcherding","year":"2021","unstructured":"Borcherding, N. et al. Mapping the immune environment in clear cell renal carcinoma by single-cell genomics. Commun. Biol. 4, 122 (2021).","journal-title":"Commun. Biol."},{"key":"43447_CR103","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jmoldx.2011.08.002","volume":"14","author":"F Wang","year":"2012","unstructured":"Wang, F. et al. RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. J. Mol. Diagn. 14, 22\u201329 (2012).","journal-title":"J. Mol. Diagn."},{"key":"43447_CR104","unstructured":"R-CoreTeam. R.: a language and environment for statistical computing. R Foundation for Statistical Computing. https:\/\/www.gbif.org\/tool\/81287\/r-a-language-and-environment-for-statistical-computing (2023)."},{"key":"43447_CR105","unstructured":"Old, S. I. Source code for subclustering, figure production in R, and scGSEA for publication \u201cPre-existing interferon gamma conditions the lung to mediate early control of SARS-CoV-2\u201d Zenodo (2023)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-43447-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-43447-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-43447-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T01:03:05Z","timestamp":1702429385000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-43447-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,12]]},"references-count":105,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["43447"],"URL":"https:\/\/doi.org\/10.1038\/s41467-023-43447-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,12]]},"assertion":[{"value":"7 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8229"}}